Additionally, mIDH1 AML exhibits increased dependence on the anti-apoptotic protein BCL-2, and the BCL-2 inhibitor venetoclax induces apoptosis and tumor regression in both in vitro and in vivo models [170]. Here, BCL2 is linked to acute myeloid leukemia.